138 related articles for article (PubMed ID: 22511796)
1. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer.
Dalle Carbonare L; Frigo A; Francia G; Davì MV; Donatelli L; Stranieri C; Brazzarola P; Zatelli MC; Menestrina F; Valenti MT
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1249-56. PubMed ID: 22511796
[TBL] [Abstract][Full Text] [Related]
2. [Detection of Runx2 mRNA expression using relatively real-time RT-PCR in papillary thyroid carcinoma].
Gong T; Wang J; Qian M; Zhou Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Feb; 27(4):193-5. PubMed ID: 23631133
[TBL] [Abstract][Full Text] [Related]
3. Transcription Factor HOXA9 is Linked to the Calcification and Invasion of Papillary Thyroid Carcinoma.
Jin Y; Kim HK; Lee J; Soh EY; Kim JH; Song I; Chung YS; Choi YJ
Sci Rep; 2019 May; 9(1):6773. PubMed ID: 31043660
[TBL] [Abstract][Full Text] [Related]
4. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
5. Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.
Lubitz CC; Parangi S; Holm TM; Bernasconi MJ; Schalck AP; Suh H; Economopoulos KP; Gunda V; Donovan SE; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ
J Mol Diagn; 2016 Jan; 18(1):100-8. PubMed ID: 26631873
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
7. Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma.
Kaptan E; Sancar Bas S; Sancakli A; Aktas HG; Bayrak BB; Yanardag R; Bolkent S
J Cell Biochem; 2017 Nov; 118(11):3911-3919. PubMed ID: 28390192
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells.
Endo T; Ohta K; Kobayashi T
J Clin Endocrinol Metab; 2008 Jun; 93(6):2409-12. PubMed ID: 18381576
[TBL] [Abstract][Full Text] [Related]
9. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
Myklebust LM; Akslen LA; Varhaug JE; Lillehaug JR
Thyroid; 2011 Nov; 21(11):1217-25. PubMed ID: 22007921
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
11. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
12. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
[TBL] [Abstract][Full Text] [Related]
13. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
[TBL] [Abstract][Full Text] [Related]
15. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
16. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas.
Kwak JY; Jeong JJ; Kang SW; Park S; Choi JR; Park SJ; Kim EK; Chung WY
Head Neck; 2013 Nov; 35(11):1630-3. PubMed ID: 23161556
[TBL] [Abstract][Full Text] [Related]
17. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of estrogen receptor-α in human papillary thyroid carcinomas studied by laser- capture microdissection and molecular biology.
Di Vito M; De Santis E; Perrone GA; Mari E; Giordano MC; De Antoni E; Coppola L; Fadda G; Tafani M; Carpi A; Russo MA
Cancer Sci; 2011 Oct; 102(10):1921-7. PubMed ID: 21707866
[TBL] [Abstract][Full Text] [Related]
19. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of lncRNA-ATB by Transforming Growth Factor β1 (TGF-β1) Promotes Migration and Invasion of Papillary Thyroid Carcinoma Cells.
Cui M; Chang Y; Du W; Liu S; Qi J; Luo R; Luo S
Med Sci Monit; 2018 Jul; 24():5152-5158. PubMed ID: 30042377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]